熱門資訊> 正文
Piper Sandler称Intra-Cellular超重，并引用卡明塔的潜力
2024-09-07 06:01
- Piper Sandler upgraded Intra-Cellular Therapies (NASDAQ:ITCI) to overweight, citing Caplyta’s sales potential.
- The investment bank said its survey of 25 psychiatrists indicated that the patient/prescription volume footprint for Caplyta as an adjunctive therapy for major depressive disorder is similar to the one being crafted for AbbVie’s (ABBV) Vraylar.
- Piper now sees potential peak U.S. sales for Caplyta near or above $4B. It noted that U.S. sales of Vraylar should be greater than $3B this year.
- “That backdrop makes for a fundamentally more benign risk/reward profile,” Piper added.
- The investment bank raised its price target to $92 from $68.
More on Intra-Cellular Therapies
- Peaking Back In On Intra-Cellular Therapies
- Intra-Cellular Therapies, Inc. (ITCI) Q2 2024 Earnings Call Transcript
- Intra-Cellular Brightens MDD Outlook With Caplyta Success
- Intra-Cellular Therapies Q2 2024 Earnings Preview
- Intra-Cellular gains after late-stage win for mood disorder therapy
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
